Cytotec

Quick links to important sections

Cytotec

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cytotec

Quick Facts

Property Description
Active Ingredient Misoprostol (INN)
Form Oral tablet, Vaginal insert
Pharmacological Class Prostaglandin Analogue
General Purpose Gastrointestinal cytoprotection, Uterine smooth muscle stimulation
Origin Synthetic compound

Identity, Classification, and Composition

Cytotec is the commercial name for this prescription-only medicine, containing the single active ingredient Misoprostol, which is classified as an antiulcer and uterotonic agent. This medication is a synthetic compound, chemically manufactured as a single-entity product. Misoprostol is supplied primarily in the form of an oral tablet for ingestion, though it is also formulated as a dedicated vaginal insert for administration via the vaginal route.

Misoprostol is classified pharmacologically as a prostaglandin analogue because it structurally mimics the naturally occurring lipid substance, prostaglandin E1 (PGE1), found throughout the body. The tablet contains the active Misoprostol ingredient combined with standard pharmaceutical excipients necessary for stability. This differentiation highlights the medicine’s unique method of acting as a substitute for a key protective signaling molecule in the body.


General Purpose and Physiological Role

The general purpose of Misoprostol is to exert controlled effects on two distinct systems in the body through its prostaglandin-like activity. It serves both an anti-secretory (acid-reducing) and cytoprotective (cell-protecting) role in the digestive tract. Its function involves promoting the formation of protective mucus and bicarbonate, which serves to reinforce the natural defense mechanisms of the stomach lining. Separately, its core physiological action includes stimulating the contraction of smooth muscle tissues, particularly in the uterus, which gives it a distinct utility in specific reproductive health contexts.

What side effects are possible with Cytotec?

Possible Side Effects and Safety Information

Cytotec (misoprostol) is associated with a distinctive safety profile. The most significant safety constraint is its potent uterotonic activity.

Serious Safety Risks and Contraindication

Black Box Warning (FDA): Misoprostol is strictly contraindicated in women who are pregnant to reduce the risk of NSAID-induced ulcers. Administration during pregnancy can cause birth defects, abortion, premature birth, or uterine rupture. The risk of uterine rupture increases with advancing gestation and in patients with a history of uterine surgery, including Cesarean delivery.

Women of childbearing potential must have a negative pregnancy test prior to starting therapy and use effective contraception throughout treatment.

Common Adverse Reactions

The most frequent adverse events, typically dose-related, affect the gastrointestinal system:

  • Diarrhea: Occurs commonly (14–40% in clinical trials) and is dose-related. It usually develops early in therapy and is often self-limiting, though severe cases resulting in dehydration have been reported rarely.
  • Abdominal Pain: Occurs commonly (13–20%), sometimes described as cramps.

Other commonly reported reactions include nausea, flatulence, and headache. Taking the medicine with food can help minimize the incidence of diarrhea.

Other Reported Adverse Events

Reported gynecological events include spotting, cramps, dysmenorrhea (painful menstruation), and menstrual disorders. Postmenopausal vaginal bleeding is also a possibility and requires diagnostic evaluation to rule out other pathology. Infrequently reported serious events include hypersensitivity reactions, myocardial infarction, and thromboembolic events.

Overdose and Emergency Response

Overdose and when to seek help

Information regarding misoprostol overdose is compiled strictly from official government regulatory sources, describing documented clinical manifestations and mandated emergency actions. Overdose presentations can affect multiple physiological systems, although the exact toxic dose in humans has not been formally determined according to official labeling.

Domain Officially Documented Clinical Signs
Gastrointestinal Abdominal pain, diarrhea, and vomiting are reported manifestations.
Systemic / CNS Signs may include sedation, tremor, convulsions, fever, and dyspnea (shortness of breath).
Cardiovascular Manifestations observed in overdose include palpitations, hypotension (low blood pressure), and bradycardia (slow heart rate).

Overdose during pregnancy carries a serious, specific risk due to the drug's uterotonic properties. The regulatory profile notes potential outcomes such as uterine hypertonia, uterine rupture, and fetal death.

Immediate Actions and Management

If an overdose is suspected, seek immediate medical attention or call the Poison Help line without delay. Regulatory information mandates that patients must undergo hospital monitoring and close observation. Management of misoprostol overdose is symptomatic and supportive, focusing on treating the observed clinical signs. The official documentation states that no specific antidote is known, and it is considered unlikely that dialysis would be an appropriate treatment for overdosage.

Therapeutic Uses of Cytotec

Main Uses and Benefits of Cytotec

Cytotec, which contains the active ingredient misoprostol, is primarily utilized in clinical settings for its protective effects on the gastrointestinal lining and its actions on uterine tissue. Originally developed for gastric health, its applications have expanded due to its prostaglandin-like properties.

Prevention of Gastric Ulcers

The primary indication for Cytotec is the prevention of gastric ulcers in individuals who take nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen, or naproxen.

NSAIDs work by inhibiting certain enzymes, which reduces pain and inflammation but also decreases the production of protective prostaglandins in the stomach. This reduction can lead to a weakened stomach lining and the formation of ulcers. Cytotec acts as a synthetic prostaglandin E1 analogue, performing several functions to maintain gastric integrity:

  • Acid Reduction: It helps decrease the amount of acid secreted by the stomach.
  • Mucosal Protection: It stimulates the production of protective mucus and bicarbonate.
  • Blood Flow Support: It helps maintain adequate blood flow to the stomach lining, which is essential for tissue repair and health.

Gynecological and Obstetric Applications

Beyond its gastrointestinal uses, Cytotec is frequently employed in reproductive medicine because it causes the cervix to soften and the uterus to contract. These properties make it a tool for several specific medical needs:

  • Labor Induction: In certain clinical scenarios where a pregnancy needs to be initiated, it is used to ripen the cervix and stimulate contractions.
  • Management of Early Pregnancy Loss: It is used to help the body expel tissue following a miscarriage, providing a non-surgical option for patients.
  • Postpartum Care: It may be used to manage or prevent heavy bleeding after childbirth by encouraging the uterus to contract and firm up.
  • Cervical Ripening: It is sometimes used prior to surgical procedures involving the uterus to soften the cervical opening, making the procedure safer and more accessible.

Therapeutic Benefits

The benefit of using Cytotec lies in its ability to provide a non-invasive pharmacological approach to conditions that might otherwise require more intensive intervention or lead to serious complications. For patients requiring long-term pain management with NSAIDs, it offers a way to continue necessary medication while lowering the risk of internal bleeding or ulceration. In obstetric care, it provides a predictable method for managing various stages of pregnancy and delivery under medical supervision.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Cytotec — Official Regulatory Information

This map summarizes the official population eligibility and non-eligibility requirements for Cytotec (Misoprostol) based strictly on governmental regulatory documents.


Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adults (18 years and older) requiring prophylaxis for NSAID-induced gastric ulcers.
  • Older adults (Geriatric): The usual dosage may be used, though patients should be closely monitored.

Populations for whom use is not recommended (if applicable):

  • Children and adolescents under 18 years: Safety and efficacy are not established for the antiulcer indication.
  • Patients who are breastfeeding (due to excretion of the active metabolite in breast milk).

Populations for whom use is contraindicated:

  • Pregnant women or women in whom pregnancy has not been excluded.
  • Patients with known hypersensitivity to misoprostol or other prostaglandins.

Eligibility-related restrictions:

  • Women of childbearing potential: Must have a negative serum pregnancy test and must use effective contraceptive measures during treatment.
  • Patients with renal impairment: No routine dosage adjustment is required in mild to moderate impairment, but monitoring is necessary.

Connection to the overall eligibility profile

The official regulatory profile for Cytotec is fundamentally structured by the absolute contraindication in pregnancy, which requires strict eligibility rules for all women of childbearing potential. For the general adult population, eligibility is permitted under standard conditions, but conditional limitations regarding age (not established in pediatrics) and organ function (caution in renal impairment) define the boundaries of use as documented by governmental authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacodynamic and Timing Restrictions

The official regulatory profile for Cytotec interactions centers on pharmacodynamic potentiation and specific pharmacokinetic alterations documented in government sources. Co-administration with Oxytocic Agents may augment their activity due to misoprostol's prostaglandin analogue properties. To manage this potential for pharmacodynamic synergism, an administration timing rule requires that oxytocin infusion must be delayed by at least 4 hours following the last oral misoprostol dose. A specific pharmacodynamic constraint exists with Magnesium-Containing Antacids, which are associated with an increased risk of diarrhea and must be officially recommended for avoidance.


Pharmacokinetic Alterations and Population Notes

Pharmacokinetic data indicates that systemic exposure is altered by several factors. Taking Cytotec with a high-fat meal or general Antacids diminishes the maximum plasma concentration ( C max) of misoprostol acid, defining an administration constraint. Conversely, clearance is significantly reduced in certain populations: in patients with Renal Impairment, pharmacokinetic studies show an approximate doubling of systemic exposure ( AUC) and C max. An increased exposure is also noted in elderly patients (over 64 years of age). Official regulatory documents confirm the lack of clinically significant pharmacokinetic interaction with several common nonsteroidal anti-inflammatory drugs, including ibuprofen and diclofenac. This information structures the mandatory co-administration restrictions.

Mechanism of Action

Cytotec (misoprostol) is a synthetic analog of prostaglandin E1 (PGE1) that exerts its effects by acting as an agonist on specific prostaglandin receptors (EP receptors) in target tissues. Its mechanism involves two primary domains: the gastrointestinal system and the uterus.

Inhibition of Gastric Acid Secretion

Within the stomach lining, misoprostol binds to the EP3 receptor on gastric parietal cells. This initiates a signal cascade that inhibits adenylate cyclase. This action reduces the intracellular concentration of the secondary messenger cAMP, a molecule essential for stimulating acid production. This mechanism mediates a decrease in the secretion of gastric acid.

Enhancement of Gastric Mucosal Protection

In the gastric and duodenal mucosa, EP receptor activation on non-parietal cells modulates the local environment by increasing the secretion of bicarbonate and protective mucus. Furthermore, it is associated with increased mucosal blood flow, thereby engaging regulatory systems that influence the status and maintenance of the gastric barrier.

Modulation of Uterine Smooth Muscle Activity

In reproductive tissues, the drug acts on EP2 and EP3 receptors in the myometrium (uterine muscle). Receptor activation initiates an increase in the intracellular concentration of calcium ions ( Ca^2+). This rise in Ca^2+ concentration is the critical mechanistic step that triggers smooth muscle contraction and, separately, influences the molecular processes of cervical matrix degradation and alteration.

Dosage and Administration Information

Official Use Protocol for Cytotec

Cytotec (misoprostol) is administered as an oral tablet for its use in reducing the risk of gastric ulcers associated with nonsteroidal anti-inflammatory drug (NSAID) therapy. The available oral strengths are 100 micrograms (µg) and 200 micrograms (µg).


Labeled Administration Regimen

The standard regimen requires a dose of 200 µg to be taken four times daily (q.i.d.). This frequency pattern is established to maintain drug levels throughout the day. The tablets must be taken with food, a contextual intake condition specified to minimize gastrointestinal upset. Furthermore, the final dose of the day is instructed to be administered at bedtime.


Duration and Adjustments

The medicine should be continued for the entire duration of NSAID therapy. For patients with renal impairment, adjustment of the dosing schedule is not routinely needed, but if the standard 200 µg dose is not tolerated, a dose reduction to 100 µg per administration may be implemented. A special procedural condition for women of childbearing potential requires that administration must begin on the second or third day of the menstrual cycle. This set of instructions dictates the approach to oral dosing, scheduling, and duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cytotec (Misoprostol)


Research Evidence on Preventing NSAID-Associated Ulcers

The research exploring Misoprostol's use in ulcer prevention has relied on long-term, controlled clinical trials. These studies compared Misoprostol against a non-treatment (placebo) group or against other common anti-ulcer medications. Researchers focused on endoscopic measurements to assess the rate at which ulcers were reported in the stomach and the upper part of the small intestine. A key outcome monitored was the reported occurrence of serious upper gastrointestinal complications like bleeding or perforation over the study period.

Studies reported measurements of ulcer incidence that were tracked over observation periods lasting up to one year. However, Reports from the studies noted that patients receiving Misoprostol frequently reported certain GI symptoms, which often led to a higher rate of patient withdrawal from the study compared to patients on placebo.


Research Evidence on Uterine Effects and Labor Induction

Misoprostol's effect on the uterus was studied for labor induction and cervical preparation in pregnant individuals at term. The research base is extensive, relying on a large volume of Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. Studies monitored key outcomes such as the time from administration to delivery and the rate of Cesarean section.

Reports documented measurements of the time interval between administration and delivery and the frequency of Cesarean deliveries. Trials described measurements of uterine activity, noting differences in reported hyperstimulation based on the route of administration (oral versus vaginal) and the dose used. A key limitation is the high degree of heterogeneity across study protocols in dose and route, meaning data are still emerging regarding the optimal approach.


Key Uncertainties and Research Gaps

The body of research highlights areas where certainty remains low or data are insufficient. A major research limitation in the ulcer prevention field is that the evidence is primarily focused on the populations studied, and there is limited information on long-term outcomes beyond one year. Follow-up durations were limited for sustained, multi-year outcomes in the GI setting, and research on uterotonic uses focuses only on the acute phase.

For all studied situations, comparative evidence is lacking for every possible alternative treatment. In the GI trials, certain large studies included a significant proportion of older adults; however, data for certain groups remain insufficient to draw broad conclusions.

Frequently Asked Questions (FAQ)

Common questions about Cytotec (FAQ)


Q: Is Cytotec available over the counter?

No, official regulatory documents state that Cytotec is classified as a prescription-only medicine. This indicates it must be obtained through a licensed healthcare professional and is not available for purchase over the counter.


Q: How long does Cytotec stay in your system?

Information from clinical pharmacology studies indicates that the active substance from Cytotec is eliminated relatively quickly. The terminal half-life of the active metabolite, which is a measure of how fast the body processes and removes the drug, is typically around 20 to 40 minutes in healthy individuals.


Q: Are there any specific foods to avoid when taking Cytotec?

Official prescribing information notes that taking the medicine alongside a high-fat meal or certain antacids can potentially reduce the amount of the active ingredient that reaches its maximum concentration in the blood. Information about taking the medicine with food is provided in the official administration guidelines.


Q: Can Cytotec be used by men?

Yes, Cytotec is approved for the purpose of reducing the risk of ulcers caused by NSAIDs, a condition that affects both male and female patients. The most significant restriction on use is the strict contraindication for pregnant women, but there is no exclusion based on male sex for the approved indication.


Q: Is Cytotec safe for people with high blood pressure?

Regulatory documents advise that caution should be used when administering Cytotec to individuals with pre-existing cardiovascular diseases. The official prescribing information advises caution for patients with cardiovascular disease but does not list high blood pressure as a specific contraindication.


Q: Does Cytotec cause fatigue or drowsiness?

Official reports of adverse events list dizziness and headache as central nervous system effects. While less frequent, reports have included instances of drowsiness and fatigue; the exact frequency of these symptoms is not specified in the official information.


Q: What is the purpose of the different strengths of Cytotec?

Cytotec is supplied in two oral strengths: 100 mu g and 200 mu g tablets. Regulatory guidelines define the 200 mu g dose as the standard regimen for the approved use. The 100 mu g strength may be used as a potential reduction if the higher dose is not tolerated.


Q: Do older adults need a different dose of Cytotec?

The official product label indicates that the usual dosage may be used for older adults (geriatric). However, monitoring may be advised, as increased systemic exposure (higher levels of the drug in the body) has been noted in this population.


Q: Is there a generic version of Cytotec?

Yes, the active ingredient in Cytotec, which is called misoprostol, is available as a generic drug. This means there are versions of the medication available under its chemical name, in addition to the Cytotec brand name.


Q: What are the signs of a serious reaction to Cytotec?

Official reports indicate that infrequently reported serious adverse events have included types of hypersensitivity reactions, such as swelling, hives, or breathing difficulty. Other serious events noted in the documentation include myocardial infarction (heart attack) and thromboembolic events (blood clots).


Q: What is the risk of overdose with Cytotec?

According to official information on overdosage, symptoms that have been reported can include gastrointestinal issues like diarrhea and abdominal pain. Other possible effects noted include sleepiness, tremor, seizures, shortness of breath, fever, and low blood pressure.


Q: How long after stopping Cytotec can I try to become pregnant?

Official regulatory documents place a strong emphasis on the requirement for women of childbearing potential to use effective contraception throughout the entire course of therapy. While a negative pregnancy test is required at the start of treatment, the documentation does not specify a mandatory waiting period for attempting to conceive after the medication has been discontinued.


Q: Can people with kidney problems use Cytotec?

Official documents state that patients with renal impairment may show increased systemic exposure, meaning the drug stays in the body longer. However, the label indicates that no routine dosage adjustment is required in cases of mild to moderate impairment, and monitoring may be required, as noted in the regulatory documents.


Q: How quickly does Cytotec start to work?

In terms of its approved use, regulatory studies indicate that the acid-reducing (antisecretory) effect of Cytotec is noticeable about 30 minutes after a single oral dose is administered. This effect is described as lasting for at least three hours.


Q: Are there long-term side effects associated with Cytotec use?

Official regulatory information on adverse effects is based primarily on data collected during clinical trials lasting up to one year. There are no specific human data reported on side effects or safety for treatment periods extending beyond one year.


Q: Can Cytotec be used if I am breastfeeding?

Regulatory documents state that Cytotec's active metabolite is excreted into breast milk. Due to the possibility of adverse effects on the nursing infant, the official eligibility map states that its use is not recommended for patients who are breastfeeding.

How should Cytotec be stored and disposed of?

The official storage requirements for Cytotec (misoprostol) tablets focus on maintaining stability and ensuring safety. The medication must be kept at room temperature, away from excess heat. Protection from moisture and light is mandatory, and the container must remain tightly closed to prevent degradation. It is a critical requirement to keep this medication out of the reach of children, utilizing safety caps and secure storage locations.

For disposal, do not flush unused or expired tablets down the toilet or pour them into a drain. Patients should consult a healthcare professional or pharmacist and utilize an approved drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cytotec found in:

A-Z Index: